Navigation Links
Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting

- Presentation to highlight milestones including phase III development of

'GI-friendly' NSAIDs for mild to moderate pain -

PALO ALTO, Calif., Oct. 5 /PRNewswire/ --

What: Horizon Therapeutics, Inc. is pleased to announce that

George Tidmarsh, M.D., Ph.D., chief executive officer, will

showcase Horizon's corporate and clinical milestones,

including its recent completion of Series C financing, and

provide an update on the development of the Company's

product pipeline during an Open House Podium Presentation

at BioPartnering Europe (BPE). Immediately following the

presentation Dr. Tidmarsh will be available to field

questions and provide more detailed information on Horizon


BPE was first held in London in 1993 as a partnership

between the U.S. Commercial Service and Technology Vision

Group LLC to bring about closer ties between American and

European biotechnology companies. From the beginning, BPE

has attracted the support of leading pharmaceutical,

biotechnology, financial and service companies that have

all contributed to making BPE one of the leading

independent partnering events in the world. BPE has a high

rate of sponsor retention, which indicates its prominent

position on the annual conference calendar for many

industry leaders.

When: Monday, October 8, 2007

9:30 a.m. - 12:45 p.m. Open House Podium Presentation

(10:45-10:55 a.m. Horizon presentation)

Where: London, England

QEII Conference Centre

Abbey Room West - Stream 1

Spokespeople: George Tidmarsh, M.D., Ph.D., co-founder and CEO of Horizon


Barry Golombik, co-founder of Horizon Therapeutics

Contact: Julie Normart

WeissComm Partners


About Horizon Therapeutics:

Horizon Therapeutics, Inc. is a late stage biopharmaceutical company focused on the rapid development and commercialization of therapeutic treatments for mild-to-moderate pain management. The Company is building a novel portfolio of therapies through innovative combinations of approved pharmaceutical products that seek to improve safety, efficacy, and patient compliance. Its lead product candidate, HZT-501, entered Phase 3 trials in 2007. In addition to HZT-501, Horizon has a pipeline of follow-on pain combination products in earlier stages of development. For more information visit

SOURCE Horizon Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New hope on the Horizon for People Wishing to Quit Smoking
2. A new horizon
3. Conjoined Indian Twins See Hope On The Horizon
4. Stem cell cure for peripheral vascular disease: New hope on the horizon
5. Oral Flu Vaccine On The Horizon In Russia
6. Rescheduled: Aerial Mosquito Treatment for Philadelphia
7. First Keyhole Heart Valve Surgery Scheduled in Britain
8. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
9. Researchers Present Ways To Reduce The Risk Of Dementia
10. Researchers Present Data Regarding The Efficiency Of Herbs
11. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
Post Your Comments:
(Date:11/27/2015)... ... ... Lizzie’s Lice Pickers just announced a special promotion that will run throughout ... of lice treatment product. In addition, customers will receive a complimentary head Check when ... is a sure way to ruin the holidays, so we encourage all of our ...
(Date:11/27/2015)... ... ... No.1 Herpes-only dating community in the world, revealed that over 50% of its members are ... people under the age of 50 – or 67% of the population - are infected ... HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of ...
(Date:11/27/2015)... ... , ... A simply groundbreaking television series, "Voices in America", which is hosted ... array of issues that are presently affecting Americans. Dedicated to providing the world with ... changing the subjects consumers focus on, one episode at a time. , In ...
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... Commission on Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic ... list of CAAHEP accredited colleges, as only one of twelve colleges and universities in ...
(Date:11/27/2015)... ... ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces his search for ... of Joplin's most famous and beautiful concert posters. The concert was held on March ... The According to Hawley, "It is hard to believe that Joplin's stardom was only ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Nov. 26, 2015 ... the addition of the "2016 Global ... Test, Country Volume and Sales Segment Forecasts, ... Opportunities" report to their offering. ... addition of the "2016 Global Tumor ...
(Date:11/26/2015)... , November 26, 2015 ... new combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... combination approach blends immunotherapy with Bremachlorin-photodynamic therapy for advanced ... has found that immunotherapy can be efficiently combined ...
(Date:11/26/2015)... 2015 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ... demands kidney transplantation is expected to boost the market growth, ... organ transplantation. --> 3D bioprinting market is ... a new report by Grand View Research Inc. Rising prevalence ...
Breaking Medicine Technology: